Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sonnet BioTherapeutics Holdings (SONN)
NASDAQ:SONN
RESEARCH TOOLSreports
Holding SONN?
Track your performance easily
SONN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.37 - $18.71
Previous Close$6.01
Volume9.15K
Average Volume (3M)27.61K
Market Cap
$3.91M
Enterprise Value$458.57K
Total Cash (Recent Filing)$3.60M
Total Debt (Recent Filing)$150.19K
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Dec 12, 2024EPS Estimate
-$5.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-24.20
Shares Outstanding650,313
10 Day Avg. Volume35,674
30 Day Avg. Volume27,606
Standard Deviation0.28
R-Squared0.03
Alpha-0.11
Financial Highlights & Ratios
Price to Book (P/B)1.49
Price to Sales (P/S)69.94
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue56.96
Enterprise Value/Gross Profit4.59
Enterprise Value/Ebitda-1.41
Forecast
1Y Price Target
$30.00Price Target Upside399.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Sonnet BioTherapeutics Holdings News
PremiumCompany Announcements
Sonnet BioTherapeutics Maintains Nasdaq Listing Compliance
PremiumCompany Announcements
Sonnet BioTherapeutics’ Strategic Deal to Develop DPN Treatment
Ownership Overview
6.50%
Insiders
3.66% Mutual Funds
― Other Institutional Investors
89.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SONN FAQ
What was Sonnet BioTherapeutics Holdings’s price range in the past 12 months?
Sonnet BioTherapeutics Holdings lowest stock price was $4.37 and its highest was $18.71 in the past 12 months.
What is Sonnet BioTherapeutics Holdings’s market cap?
Currently, no data Available
When is Sonnet BioTherapeutics Holdings’s upcoming earnings report date?
Sonnet BioTherapeutics Holdings’s upcoming earnings report date is Dec 12, 2024 which is in 37 days.
How were Sonnet BioTherapeutics Holdings’s earnings last quarter?
Sonnet BioTherapeutics Holdings released its earnings results on Aug 14, 2024. The company reported -$5.6 earnings per share for the quarter, beating the consensus estimate of -$6.12 by $0.52.
Is Sonnet BioTherapeutics Holdings overvalued?
According to Wall Street analysts Sonnet BioTherapeutics Holdings’s price is currently Undervalued.
Does Sonnet BioTherapeutics Holdings pay dividends?
Sonnet BioTherapeutics Holdings does not currently pay dividends.
What is Sonnet BioTherapeutics Holdings’s EPS estimate?
Sonnet BioTherapeutics Holdings’s EPS estimate is -$5.04.
How many shares outstanding does Sonnet BioTherapeutics Holdings have?
Sonnet BioTherapeutics Holdings has 650,313 shares outstanding.
What happened to Sonnet BioTherapeutics Holdings’s price movement after its last earnings report?
Sonnet BioTherapeutics Holdings reported an EPS of -$5.6 in its last earnings report, beating expectations of -$6.12. Following the earnings report the stock price went up 1.599%.
Which hedge fund is a major shareholder of Sonnet BioTherapeutics Holdings?
Currently, no hedge funds are holding shares in SONN
---
Sonnet BioTherapeutics Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.00 (399.17% Upside)
$30.00 (399.17% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.76%
12-Months-Change
Fundamentals
Return on Equity
-264.57%
Trailing 12-Months
Asset Growth
-42.23%
Trailing 12-Months
Company Description
Sonnet BioTherapeutics Holdings
Sonnet BioTherapeutics (NASDAQ:SONN) is a clinical-stage biotechnology company that is focused on the development of drugs for the treatment of cancer.
---
SONN Stock 12 Month Forecast
Average Price Target
$30.00
▲(399.17% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
Cellectar Biosciences
―
TRACON Pharmaceuticals
―
ADC Therapeutics
―
Best Analysts Covering SONN
1 Year
1 Year Success Rate
1/17 ratings generated profit
1 Year Average Return
-75.04%
reiterated a buy rating 3 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 5.88% of your transactions generating a profit, with an average return of -75.04% per trade.
---